TechConnect Innovation Program

Nanoparticles-based combinatorial therapy for breast cancer

The American University in Cairo (AUC), Cairo, Egypt

TECHNOLOGY SUMMARY

The present invention entails the development of NanoParticles (NPs)-based combinatorial therapy composed of Doxorubicin (DOX) loaded on core-shell silver/ polymeric (PVA, PEG, and PVP) NPs. This NPs-based combinatorial therapy has potent anticancer activity aimed at achieving maximum therapeutic efficacy, while minimizing DOX’s dose and systemic toxicity.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

FIGURES OF MERIT

Value Proposition: Our NPs-based combinatorial therapy have the ability to (1) prolong DOX’s half-life resulting in increasing DOX’ bioavailability at tumor site, (2) provide a targeting drug delivery which allows selective delivery of DOX and NPs to cancer cells leaving the normal cells untouched and hence reduces DOX’s toxicity,

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Showcase Booth #: 641

Website: http://www.aucegypt.edu

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date:

Primary Sources of Funding: University

Looking for: Both Funding and Development Partners